Covalon Technologies Ltd. (COV.V)
CAD 2.3
(-4.17%)
CAD 2.3
(-4.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.49 Million CAD | 56.11% |
| 2022 | -8.1 Million CAD | -627.0% |
| 2021 | 1.53 Million CAD | 131.49% |
| 2020 | -6.63 Million CAD | 35.87% |
| 2019 | -7.61 Million CAD | -485.95% |
| 2018 | 1.97 Million CAD | -5.14% |
| 2017 | 1.97 Million CAD | 176.17% |
| 2016 | -2.86 Million CAD | -428.85% |
| 2015 | -516.55 Thousand CAD | -118.86% |
| 2014 | 2.59 Million CAD | 495.94% |
| 2013 | -677.64 Thousand CAD | 76.49% |
| 2012 | -3.63 Million CAD | 9.55% |
| 2011 | -3.25 Million CAD | -3223.17% |
| 2010 | -1.59 Million CAD | 102.27% |
| 2009 | -4.7 Million CAD | -35.46% |
| 2008 | -3.39 Million CAD | -7.5% |
| 2007 | -3.15 Million CAD | -51.82% |
| 2006 | -2.07 Million CAD | -19.39% |
| 2005 | -1.74 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.23 Million CAD | 49.25% |
| 2024 Q2 | 1.73 Million CAD | 228.75% |
| 2024 Q3 | 1.72 Million CAD | -0.5% |
| 2023 Q1 | -105.76 Thousand CAD | 96.98% |
| 2023 Q4 | -2.64 Million CAD | -736.94% |
| 2023 Q2 | -488.46 Thousand CAD | -361.83% |
| 2023 FY | - CAD | 56.11% |
| 2023 Q3 | -316.44 Thousand CAD | 35.22% |
| 2022 Q4 | -3.5 Million CAD | -151.9% |
| 2022 Q3 | -1.38 Million CAD | 36.21% |
| 2022 FY | - CAD | -627.0% |
| 2022 Q1 | -1.03 Million CAD | -65.37% |
| 2022 Q2 | -2.17 Million CAD | -109.59% |
| 2021 Q4 | -628.67 Thousand CAD | -143.38% |
| 2021 Q1 | 37.37 Thousand CAD | 102.2% |
| 2021 FY | - CAD | 131.49% |
| 2021 Q2 | 821.85 Thousand CAD | 2098.82% |
| 2021 Q3 | 1.44 Million CAD | 76.33% |
| 2020 Q4 | -1.69 Million CAD | -295.82% |
| 2020 Q3 | 865.92 Thousand CAD | 125.46% |
| 2020 FY | - CAD | 35.87% |
| 2020 Q2 | -3.4 Million CAD | -418.69% |
| 2020 Q1 | -655.61 Thousand CAD | 78.81% |
| 2019 Q2 | 20.41 Thousand CAD | 101.4% |
| 2019 FY | - CAD | -485.95% |
| 2019 Q1 | -1.45 Million CAD | -167.38% |
| 2019 Q3 | -3.09 Million CAD | -15245.21% |
| 2019 Q4 | -3.09 Million CAD | -0.08% |
| 2018 Q2 | -402.17 Thousand CAD | -167.28% |
| 2018 Q3 | 2.32 Million CAD | 677.39% |
| 2018 FY | - CAD | -5.14% |
| 2018 Q1 | 597.75 Thousand CAD | 82.08% |
| 2018 Q4 | -543.64 Thousand CAD | -123.41% |
| 2017 Q4 | 328.29 Thousand CAD | -46.53% |
| 2017 FY | - CAD | 176.17% |
| 2017 Q1 | 604.99 Thousand CAD | 128.74% |
| 2017 Q2 | 539.08 Thousand CAD | -10.89% |
| 2017 Q3 | 613.98 Thousand CAD | 13.89% |
| 2016 Q1 | 386.3 Thousand CAD | 155.03% |
| 2016 Q4 | -2.1 Million CAD | -3543.25% |
| 2016 Q3 | -57.77 Thousand CAD | 93.95% |
| 2016 Q2 | -954.45 Thousand CAD | -347.07% |
| 2016 FY | - CAD | -428.85% |
| 2015 FY | - CAD | -118.86% |
| 2015 Q3 | -45.15 Thousand CAD | -112.25% |
| 2015 Q4 | -701.94 Thousand CAD | -1454.51% |
| 2015 Q2 | 368.54 Thousand CAD | 367.45% |
| 2015 Q1 | -137.79 Thousand CAD | 84.01% |
| 2014 Q3 | -151.71 Thousand CAD | -128.7% |
| 2014 Q4 | -861.77 Thousand CAD | -468.04% |
| 2014 FY | - CAD | 495.94% |
| 2014 Q1 | 3.22 Million CAD | 1574.65% |
| 2014 Q2 | 528.67 Thousand CAD | -83.6% |
| 2013 Q2 | -484.81 Thousand CAD | 32.56% |
| 2013 Q3 | 319.23 Thousand CAD | 165.85% |
| 2013 FY | - CAD | 76.49% |
| 2013 Q4 | 192.53 Thousand CAD | -39.69% |
| 2013 Q1 | -718.85 Thousand CAD | 48.88% |
| 2012 Q3 | -650.18 Thousand CAD | -22.97% |
| 2012 Q4 | -1.4 Million CAD | -116.28% |
| 2012 FY | - CAD | 9.55% |
| 2012 Q1 | -730.38 Thousand CAD | 39.78% |
| 2012 Q2 | -528.71 Thousand CAD | 27.61% |
| 2011 Q2 | -357.35 Thousand CAD | 35.56% |
| 2011 Q1 | -554.51 Thousand CAD | 46.99% |
| 2011 FY | - CAD | -3223.17% |
| 2011 Q4 | -1.21 Million CAD | -7.4% |
| 2011 Q3 | -1.12 Million CAD | -216.04% |
| 2010 Q1 | -270.18 Thousand CAD | 65.03% |
| 2010 Q4 | -1.04 Million CAD | -311.63% |
| 2010 Q3 | -254.13 Thousand CAD | -117.06% |
| 2010 Q2 | 1.48 Million CAD | 651.37% |
| 2010 FY | - CAD | 102.27% |
| 2009 FY | - CAD | -35.46% |
| 2009 Q1 | -1.38 Million CAD | -69.6% |
| 2009 Q3 | -1.12 Million CAD | 20.58% |
| 2009 Q2 | -1.41 Million CAD | -1.92% |
| 2009 Q4 | -772.61 Thousand CAD | 31.27% |
| 2008 Q1 | -924 Thousand CAD | 24.45% |
| 2008 FY | - CAD | -7.5% |
| 2008 Q3 | -720.11 Thousand CAD | 42.08% |
| 2008 Q2 | -1.24 Million CAD | -34.56% |
| 2008 Q4 | -818.83 Thousand CAD | -13.71% |
| 2007 Q1 | -389.31 Thousand CAD | 39.63% |
| 2007 Q3 | -990.52 Thousand CAD | -78.73% |
| 2007 Q4 | -1.22 Million CAD | -23.48% |
| 2007 Q2 | -554.19 Thousand CAD | -42.35% |
| 2007 FY | - CAD | -51.82% |
| 2006 Q3 | -518.7 Thousand CAD | -5.37% |
| 2006 FY | - CAD | -19.39% |
| 2006 Q4 | -644.83 Thousand CAD | -24.32% |
| 2006 Q1 | -414.83 Thousand CAD | 56.26% |
| 2006 Q2 | -492.26 Thousand CAD | -18.67% |
| 2005 Q4 | -948.45 Thousand CAD | -205.17% |
| 2005 Q2 | -314.67 Thousand CAD | -98.82% |
| 2005 FY | - CAD | 0.0% |
| 2005 Q1 | -158.26 Thousand CAD | 0.0% |
| 2005 Q3 | -310.79 Thousand CAD | 1.23% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Arch Biopartners Inc. | -430.71 Thousand CAD | -710.651% |
| Hemostemix Inc. | -1.94 Million CAD | -79.447% |
| Universal Ibogaine Inc. | -4.6 Million CAD | 24.217% |
| Kane Biotech Inc. | -3.23 Million CAD | -7.952% |
| MedMira Inc. | -1.57 Million CAD | -121.376% |
| Marvel Biosciences Corp. | -2.25 Million CAD | -55.045% |
| NervGen Pharma Corp. | -17.72 Million CAD | 80.297% |
| XORTX Therapeutics Inc. | -6.46 Million CAD | 46.022% |